Is TRT Covered by Insurance? What Plans Check Before They Pay for Testosterone, and Why Enclomiphene Usually Isn't Covered

TRT is often covered by insurance when a man has a documented diagnosis of low testosterone: symptoms plus two early morning total testosterone results below 300 ng/dL. Coverage usually runs through prior authorization, and enclomiphene is rarely covered because it has no FDA approval.

Is TRT covered by insurance? Often it is, but coverage depends on a documented diagnosis rather than on symptoms alone. Testosterone products are FDA-approved prescription drugs, so many commercial plans and Medicare Part D plans list them on their formularies. What a plan wants to see is the diagnosis the guidelines describe: symptoms plus two early morning total testosterone results below 300 ng/dL, the cutoff used by the American Urological Association (AUA).

The gap between covered and uncovered care is large. A 2022 study in the Journal of Sexual Medicine by Jesse and colleagues priced 12 months of intramuscular testosterone at $1,586 to $4,200 through three direct-to-consumer telemedicine platforms, compared with $134.01 to $1,333.04 at a tertiary medical center under different insurance models. The rest of this article explains what insurers typically check, why some men are turned down, and why enclomiphene sits outside most coverage altogether.

TRT is covered by many insurance plans when it is prescribed for diagnosed hypogonadism with an FDA-approved testosterone product. Each plan sets its own rules in its formulary and coverage policy, so the only definitive answer for a given man comes from his plan's drug list and prior authorization form. Coverage tends to fail when the paperwork does not show a confirmed diagnosis, or when the requested product is not on the formulary.

Testosterone's FDA label shapes what insurers will accept. On February 28, 2025, the FDA announced class-wide labeling changes for testosterone products: it added the results of the TRAVERSE trial, removed language from the Boxed Warning about an increased risk of adverse cardiovascular outcomes, and added a new warning about increased blood pressure. The FDA also kept the Limitation of Use language for age-related hypogonadism, which matters because plans often follow the label when they decide what counts as a covered use.

Testosterone is rarely covered without a documented low testosterone diagnosis. The AUA guideline says clinicians should use a total testosterone level below 300 ng/dL as a reasonable cut-off in support of the diagnosis, and that the diagnosis should be made only after two total testosterone measurements taken on separate occasions, both in the early morning. Statement 2, the two-test rule, carries the guideline's strongest grade: a Strong Recommendation with Grade A evidence.

The Endocrine Society's 2018 guideline by Bhasin and colleagues sets a similar bar. It recommends diagnosing hypogonadism only in men with symptoms and signs of testosterone deficiency and unequivocally and consistently low testosterone, measured with fasting morning total testosterone on an accurate assay and repeated to confirm. When total testosterone sits near the lower limit of normal, the Endocrine Society recommends adding a free testosterone result. Our guide to testing testosterone accurately covers timing and the mistakes that produce a false low.

Prior authorization for TRT is a request the prescriber sends to the plan before the pharmacy fills the prescription, showing that the patient meets the plan's criteria. A plan's form typically asks for the lab values, dates and symptoms in the table above. If the form is incomplete, the claim is usually denied or sent back, which is the most common reason a covered drug ends up costing cash.

A Veterans Affairs study shows how a prior authorization drug request works in practice. Narla and colleagues reported in Federal Practitioner in 2021 that VA Puget Sound introduced a testosterone order template tied to its prior authorization drug request. Before the template, only 20 of 80 eligible veterans (25%) had a completed request. After the template, and after alternative ordering routes were closed, 13 of 19 (68%) did. The share of veterans with two or more low testosterone results plus LH and FSH measured rose from 23% before the template to 41% and 37% in the two later periods.

TRT through a medical center that bills insurance generally costs less over a year than TRT through a cash-pay telemedicine platform. In the Jesse study, a year of intramuscular testosterone cost $1,586 to $4,200 across the three platforms (Hone, Regenex Health and TRT Nation), and $134.01 to $1,333.04 at a tertiary center depending on the insurance model. The authors wrote that patients with private insurance or Medicare should be counseled that ongoing telemedicine treatment will likely cost more than care that can use insurance coverage.

The Jesse study has clear limits. It looked at only three telemedicine platforms, and its tertiary center estimates came from one institution's online cost estimator with a single type of private and public insurance. The figures show the direction of the gap rather than what any particular man will pay. The study also found that the platforms' initial evaluation and follow-up were largely similar to practice guidelines, so the main difference was cost.

Testosterone blood tests are usually billed to insurance like other lab work, and the insured price tends to be lower than the self-pay price. DeMasi and colleagues studied hospital price transparency data in the International Journal of Impotence Research (2026). Of 6700 hospitals, 51.7% reported at least one testosterone test price. The median price was $84.90 for total testosterone and $92.27 for free testosterone, with commercial insurance at $79.43 and self-pay at $98.00.

Prices for testosterone testing varied widely. In the DeMasi analysis, hospitals in competitive markets and larger hospitals tended to charge less, and nearly half of hospitals did not report prices at all despite the 2021 CMS Hospital Price Transparency Regulation. Since the AUA guideline calls for two tests before a diagnosis, plus hematocrit and often PSA, the lab bill can add up for a man paying out of pocket.

Medicare Part D drug plans do pay for testosterone prescriptions, subject to each plan's formulary and rules. Carter and colleagues analysed the public CMS Medicare Part D Prescriber database for testosterone claims from 2013 to 2017 (International Journal of Impotence Research, 2023). Endocrinologists and urologists most often prescribed topical testosterone (60.4% and 53.5%), while family and internal medicine physicians more often prescribed injections (59.82% and 50.69%). Oral and pellet testosterone were rarely prescribed.

Which product a plan covers can matter as much as whether it covers TRT at all. A 2025 review of the oral testosterone undecanoate products Jatenzo, Tlando and Kyzatrex by Rosen and Asanad noted that differences in dosing, titration and insurance coverage influence the choice of therapy, and that Kyzatrex offers self-pay access. Our comparison of TRT delivery methods explains how injections, gels, pellets and pills differ.

Enclomiphene is generally not covered by insurance because it is not an FDA-approved drug in the United States. According to FDA slides from the June 8, 2022 Pharmacy Compounding Advisory Committee meeting, Repros Therapeutics submitted NDA 207959 for enclomiphene citrate 12.5 mg and 25 mg capsules, and in December 2015 the company announced a Complete Response from the FDA. In January 2018 the European Medicines Agency recommended refusing authorization, finding that safety and efficacy were not sufficiently demonstrated.

Most enclomiphene sold today comes from compounding pharmacies on a cash basis. In its 2022 review, the FDA concluded that a balancing of the four evaluation criteria weighs against adding enclomiphene citrate to the 503A Bulks List, the list of bulk substances that pharmacies may use to compound. FDA reviewers listed safety concerns including cardiac and thromboembolic events, elevated estradiol, increased PSA and increased hematocrit, and noted that FDA-approved therapies are available. Our article on enclomiphene as a TRT alternative covers its fertility rationale in more detail.

The evidence on enclomiphene's effect on hormone levels is real, even without approval. A 2025 meta-analysis of randomized trials by Hohl and colleagues in Archives of Endocrinology and Metabolism found that clomiphene or enclomiphene raised total testosterone by a mean difference of 273.76 ng/dL compared with placebo in men with functional hypogonadism, with no significant difference compared with testosterone gel. Clomiphene citrate itself is an approved drug, but for other uses, so its use in men is off-label and coverage depends on the plan.

Insurance companies most often deny TRT because the request does not document a confirmed diagnosis. A single low result, an afternoon blood draw, or a missing second test falls short of the two early morning measurements the AUA guideline requires. Missing baseline labs can also hold up a request, since the AUA asks for hemoglobin and hematocrit before therapy and a PSA in men over 40.

A denial can also reflect a safety exclusion. The Endocrine Society recommends against starting testosterone in men planning fertility in the near term, or in men with breast or prostate cancer, a PSA above 4 ng/mL, a PSA above 3 ng/mL in men at higher risk of prostate cancer without urological evaluation, or an elevated hematocrit. A plan that sees one of these in the chart may decline coverage until the issue is evaluated.

This article is for educational purposes only and is not medical, legal or insurance advice. Coverage rules differ between plans and change over time, so confirm details with your insurer. Nothing here diagnoses, treats, cures or prevents any disease. Testosterone therapy and enclomiphene are discussed only in terms of what regulators and published research reported. Speak with a licensed physician before starting or changing any medication.

• American Urological Association. Evaluation and Management of Testosterone Deficiency (2024). https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
• Mulhall JP et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. Journal of Urology, 2018. https://doi.org/10.1016/j.juro.2018.03.115
• Bhasin S et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2018. https://doi.org/10.1210/jc.2018-00229
• U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products, 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products
• U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting, June 8, 2022: enclomiphene citrate slides. https://www.fda.gov/media/159042/download
• Jesse E et al. Practice Comparison and Cost Analysis of Direct-to-Consumer Telemedicine Platforms Offering Testosterone Therapy. Journal of Sexual Medicine, 2022. https://doi.org/10.1016/j.jsxm.2022.03.609
• DeMasi M et al. Testosterone testing in the United States: limited price transparency and significant variability. International Journal of Impotence Research, 2026. https://doi.org/10.1038/s41443-025-01152-0
• Narla R et al. Preliminary Evaluation of an Order Template to Improve Diagnosis and Testosterone Therapy of Hypogonadism in Veterans. Federal Practitioner, 2021. https://doi.org/10.12788/fp.0103
• Carter IV et al. Trends in testosterone prescription amongst medical specialties: a 5-year CMS data analysis. International Journal of Impotence Research, 2023. https://doi.org/10.1038/s41443-021-00497-6
• Rosen SH, Asanad K. Treatment of Symptomatic Male Hypogonadism with New Oral Testosterone Therapies: A Comparative Review of Jatenzo, Tlando, and Kyzatrex. Medicines (Basel), 2025. https://doi.org/10.3390/medicines13010001
• Hohl A et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism, 2025. https://doi.org/10.20945/2359-4292-2025-0093

Continue Reading

Related Articles

Hormones

How to Test Testosterone Accurately: Timing, Fasting and the Mistakes That Fake a Low Result

11 min read

Read Article →

TRT

Injections, Gels, Pellets, or Pills: How TRT Delivery Method Changes Everything About Treatment

13 min read

Read Article →

TRT

Enclomiphene: The TRT Alternative That Keeps Your Own Factory Running

11 min read

Read Article →